(1).jpg)
PILIHAN MANAJEMEN PASCA PAJANAN ANTRAKS PADA MANUSIA: KAJIAN LITERATUR
Abstract
Abstrak: Pilihan untuk Manajemen Pasca Pajanan Antraks pada Manusia: Sebuah Telaah Sistematis. Anthrax adalah penyakit zoonosis yang disebabkan oleh bakteri bacillus anthracis. Manajemen yang cepat dan tepat diperlukan untuk mencegah hasil yang merugikan pada pasien antraks pada manusia. Tulisan ini bertujuan untuk menjelaskan lebih lanjut terapi yang tersedia untuk manajemen pasca paparan antraks. Pencarian PubMed dilakukan untuk ‘human anthrax’ AND ‘treatment’ dari database selama 10 tahun terakhir. Sebanyak 1.449 artikel ditemukan dan 8 studi ditelaah lebih jauh. Delapan penelitian menunjukkan beberapa pilihan post-exposure prophylaxis (PEP) untuk antraks pada manusia, terutama anthrax inhalasi, yaitu imunoglobulin, raxibacumab, obiltoxaximab, dan beberapa jenis yang masih dalam pengembangan, seperti AV7909 dan Px563L. Telaah sistematis ini menunjukkan bahwa setiap penelitian menunjukkan konsentrasi antraks yang bertahan lama dan dalam jumlah yang tinggi dalam sirkulasi sehingga menunjukkan terapi imunoglobulin dapat berperan sebagai profilaksis pasca pajanan yang baik dengan menunjukkan respons imun yang adekuat pada orang sehat.
Keywords
Full Text:
PDFReferences
Bernstein, D.I. et al. (2014) ‘Immunogenicity and safety of four different dosing regimens of anthrax vaccine adsorbed for post-exposure prophylaxis for anthrax in adults’, Vaccine, 32(47), pp. 6284–6293. Available at: https://doi.org/10.1016/j.vaccine.2014.08.076.
Blackburn, J.K. et al. (2021) ‘High Case-Fatality Rate for Human Anthrax, Northern Ghana, 2005–2016’, Emerging Infectious Diseases, 27(4), pp. 1216–1219. Available at: https://doi.org/10.3201/eid2704.204496.
Hendricks, K. et al. (2022) ‘Clinical Features of Patients Hospitalized for All Routes of Anthrax, 1880–2018: A Systematic Review’, Clinical Infectious Diseases, 75(Supplement_3), pp. S341–S353. Available at: https://doi.org/10.1093/cid/ciac534.
Hendricks, K.A. et al. (2014) ‘Centers for Disease Control and Prevention Expert Panel Meetings on Prevention and Treatment of Anthrax in Adults’, Emerging Infectious Diseases, 20(2). Available at: https://doi.org/10.3201/EID2002.130687.
Katharios-Lanwermeyer, S. et al. (2016) ‘Identifying Meningitis During an Anthrax Mass Casualty Incident: Systematic Review of Systemic Anthrax Since 1880’, Clinical Infectious Diseases, 62(12), pp. 1537–1545. Available at: https://doi.org/10.1093/cid/ciw184.
Minang, J.T. et al. (2014) ‘Enhanced early innate and T cell-mediated responses in subjects immunized with Anthrax Vaccine Adsorbed Plus CPG 7909 (AV7909)’, Vaccine, 32(50), pp. 6847–6854. Available at: https://doi.org/10.1016/j.vaccine.2014.01.096.
Nagy, C.F. et al. (2016) ‘Pharmacokinetics and Tolerability of Obiltoxaximab: A Report of 5 Healthy Volunteer Studies’, Clinical Therapeutics, 38(9), pp. 2083-2097.e7. Available at: https://doi.org/10.1016/j.clinthera.2016.07.170.
Nagy, C.F. et al. (2018) ‘Safety, Pharmacokinetics, and Immunogenicity of Obiltoxaximab After Intramuscular Administration to Healthy Humans’, Clinical Pharmacology in Drug Development, 7(6), pp. 652–660. Available at: https://doi.org/10.1002/cpdd.410.
Oosterholt, S.P. and Della Pasqua, O. (2021) ‘Population pharmacokinetics of raxibacumab in healthy adult subjects’, British Journal of Clinical Pharmacology, 87(12), pp. 4718–4725. Available at: https://doi.org/10.1111/bcp.14894.
Ozer, V. et al. (2019) ‘Gastrointestinal and cutaneous anthrax: Case series’, Turkish Journal of Emergency Medicine, 19(2), pp. 76–78. Available at: https://doi.org/10.1016/j.tjem.2018.10.002.
Pilo, P. and Frey, J. (2018) ‘Pathogenicity, population genetics and dissemination of Bacillus anthracis’, Infection, Genetics and Evolution, 64, pp. 115–125. Available at: https://doi.org/10.1016/j.meegid.2018.06.024.
Pondo, T. et al. (2014) ‘Evaluation of sex, race, body mass index and pre-vaccination serum progesterone levels and post-vaccination serum anti-anthrax protective immunoglobulin G on injection site adverse events following anthrax vaccine adsorbed (AVA) in the CDC AVA human clinical trial’, Vaccine, 32(28), pp. 3548–3554. Available at: https://doi.org/10.1016/j.vaccine.2014.04.025.
Schneider, J.C. et al. (2021) ‘Safety and immunogenicity of Px563L, a recombinant anthrax vaccine candidate, in a two-dose regimen for post-exposure prophylaxis in healthy adults’, Vaccine, 39(42), pp. 6333–6339. Available at: https://doi.org/10.1016/j.vaccine.2021.08.075.
Skoura, N. et al. (2020) ‘Effect of raxibacumab on immunogenicity of Anthrax Vaccine Adsorbed: a phase 4, open-label, parallel-group, randomised non-inferiority study’, The Lancet Infectious Diseases, 20(8), pp. 983–991. Available at: https://doi.org/10.1016/S1473-3099(20)30069-4.
Wright, J.G. et al. (2014) ‘Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: A randomized trial’, Vaccine, 32(8), pp. 1019–1028. Available at: https://doi.org/10.1016/j.vaccine.2013.10.039.
Yamamoto, B.J. et al. (2016) ‘Obiltoxaximab Prevents Disseminated Bacillus anthracis Infection and Improves Survival during Pre- and Postexposure Prophylaxis in Animal Models of Inhalational Anthrax’, Antimicrobial Agents and Chemotherapy, 60(10), p. 5796. Available at: https://doi.org/10.1128/AAC.01102-16.
DOI: https://doi.org/10.33024/jmm.v7i4.11285
Refbacks
- There are currently no refbacks.
Copyright (c) 2024 Jurnal Medika Malahayati
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
